Bevacizumab in Treating Patients With Angiosarcoma

DISEASE CHARACTERISTICS: Histologically confirmed angiosarcoma Any stage disease Must be deemed not surgically resectable (complete resection) and/or no other therapeutic modality is known to be curative No angiosarcoma of a vessel wall Newly diagnosed or recurrent/refractory disease No prior tumor-related hemorrhage (any grade) Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT scan No CNS disease, brain metastases, or primary brain tumors PATIENT CHARACTERISTICS: ECOG performance status of 0 or 1 Absolute granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 gm/dL (transfusion and epoetin alfa allowed) Creatinine ≤ 1.5 times upper limit of normal (ULN) Urine protein:creatinine ratio ≤ 1.0 Total bilirubin ≤ 1.5 mg/dL Aspartate aminotransferase < 5 times ULN Alkaline phosphatase < 5 times ULN PT/INR ≤ 1.5 times ULN PTT ≤ 1.5 times ULN Fertile patients must use effective contraception Ejection fraction > 49% for patients with prior anthracycline therapy, ischemic cardiac disease, or history of heart failure No uncontrolled active infection No uncontrolled high blood pressure (defined as > 150/100 mm Hg) No symptomatic congestive heart failure (New York Heart Association class II-IV), unstable angina, cardiac arrhythmia, or myocardial infarction within the past 6 months No psychiatric illness or social situation that would limit study compliance No serious, nonhealing wound, ulcer, or bone fracture No evidence of bleeding diathesis or coagulopathy No clinically significant peripheral vascular disease Not pregnant or nursing No seizures not controlled with standard medical therapy No embolic or hemorrhagic stroke or prior transient ischemic attack No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months No significant traumatic injury within the past 6 weeks PRIOR CONCURRENT THERAPY: No prior therapy with bevacizumab or other antiangiogenesis treatment No major surgical procedure or open biopsy within the past 6 weeks No more than 2 prior chemotherapy regimens No fine-needle aspiration or core-needle biopsy or other minor surgical procedure within the past 7 days No radiotherapy within the past 28 days No concurrent chronic daily treatment with aspirin > 325 mg/day or nonsteroidal anti-inflammatory medications No concurrent warfarin or any other anticoagulant (any dose) No concurrent radiotherapy No concurrent major surgery